ArticleOncotarget2015

Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.

Xiangyan Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.